Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPC Chemoradiation for Esophageal Cancer
NCT00165490Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2004
- Primary completion
- Nov 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in esophageal cancer, sponsored by Dana-Farber Cancer Institute. Started Aug 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00165490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165490.